# Therapeutic Drug Monitoring of Digoxin in Canine Cardiac Disease: Indications and Interpretation ## Key Takeaways - Therapeutic drug monitoring (TDM) of digoxin in dogs is indicated for suspected toxicity, inadequate response, renal impairment, or dose adjustments, with a target therapeutic range of 0.7 to 3.0 ng/mL, interpreted alongside clinical signs. - Serum digoxin concentrations should be measured at steady state, 8 to 12 hours after the last oral dose, and after 5 to 7 days of consistent dosing or dose adjustment to avoid misinterpretation due to absorption or distribution phases. - Renal function is the primary determinant of digoxin clearance; dogs with renal insufficiency require dose adjustments and more frequent monitoring, with dosing interval extension being preferred over dose reduction. - Assay methodology significantly impacts measured digoxin concentrations due to variable cross-reactivity with cardioactive and inactive metabolites; clinicians should ascertain the assay used and interpret results accordingly. - Clinical signs of digoxin toxicity, including anorexia, vomiting, and arrhythmias, can overlap with worsening heart disease, necessitating prompt serum concentration measurement and withholding of the drug until results are available. - Concurrent medications such as amiodarone and verapamil can increase digoxin concentrations by 30-100%, requiring monitoring 7 days after their addition to the regimen. --- Digoxin remains a clinically useful inotropic and rate-controlling agent in canine cardiac disease, but its narrow therapeutic index and substantial interindividual pharmacokinetic variability make empirical dosing hazardous. This article provides a practical protocol for therapeutic drug monitoring (TDM) of digoxin in dogs, covering when to measure serum concentrations, how to time samples, how to interpret results in context, and how to manage toxicity when it occurs. The intended reader is the practicing veterinarian who prescribes digoxin for canine heart failure or supraventricular arrhythmias and needs a defensible, evidence-based framework for dose individualization. The central clinical question addressed here is straightforward: given a measured serum digoxin concentration in a dog, what action should the clinician take? Answering that question requires understanding the drug's pharmacokinetic behavior, the performance characteriztics of the assays used to measure it, and the relationship between serum concentration and both therapeutic effect and toxicity. This article integrates those elements into a monitoring protocol that can be applied in general practice without specialized equipment beyond a commercial immunoassay. ## At a Glance | Parameter | Recommendation | |---|---| | Primary indication for TDM | Suspected toxicity, inadequate response, renal impairment, or dose adjustment after pharmacokinetic change | | Sample timing | Steady state, 6 to 8 hours after oral dosing, before the next dose is not preferred for digoxin | | Target therapeutic range | 0.7 to 3.0 ng/mL, interpreted with clinical response | | Assay selection | Use an immunoassay with metabolite cross-reactivity proportional to biological activity | | Toxicity threshold | Concentrations above 3.0 ng/mL warrant dose reduction or withholding | | Renal function | Serum creatinine and estimated GFR guide starting dose and monitoring frequency | | Monitoring frequency | 5 to 7 days after dose initiation or change, then at intervals dictated by clinical stability | | Concurrent drugs | Amiodarone, verapamil, and some NSAIDs increase digoxin concentrations | | Toxicity management | Withhold digoxin, correct electrolyte abnormalities, manage arrhythmias, recheck levels | ## Pharmacologic Basis for Monitoring Digoxin exerts its positive inotropic effect through inhibition of myocardial Na,K-ATPase, increasing intracellular sodium and, via the sodium-calcium exchanger, intracellular calcium. The same enzyme inhibition underlies toxicity, particularly in the central nervous system and cardiac conduction tissue. The relationship between serum digoxin concentration and receptor occupancy is sufficiently predictable that serum measurement serves as a surrogate for effect at the receptor site. However, that surrogate is only valid when the assay measures the pharmacologically active species. Digoxin undergoes hepatic metabolism and renal excretion, with the parent compound and several metabolites contributing to measured immunoreactivity. The metabolites digoxigenin bisdigitoxoside, digoxigenin monodigitoxoside, and digoxigenin retain partial biological activity, while dihydrodigoxin is largely inactive. Commercial immunoassays vary substantially in how they cross-react with these metabolites. One comparative study of four immunoassays found that only the ACS assay demonstrated cross-reactivity with digoxin metabolites that paralleled their pharmacological activity, with a correlation coefficient of 0.96 against human heart receptor reactivity, whereas other assays showed correlations from 0.42 to 0.60. The clinical consequence is that an assay with high cross-reactivity to digoxigenin, which has approximately 10 percent bioactivity relative to digoxin, can overestimate the effective drug concentration and lead to inappropriate dose reduction. Clinicians should know which assay their laboratory uses and interpret results accordingly. ## Pharmacokinetic Determinants of Serum Concentration Digoxin absorption after oral administration in dogs is variable but generally adequate. The drug distributes widely, with a large volume of distribution reflecting extensive tissue binding. Elimination is predominantly renal, with a significant fraction excreted unchanged. Consequently, renal function is the single most important patient factor determining steady-state serum concentration. In geriatric dogs, age-related decline in glomerular filtration rate can reduce digoxin clearance even when serum creatinine remains within the reference interval, and this population is at particular risk of accumulation. The elimination half-life of digoxin in dogs is approximately 24 to 36 hours, which dictates that steady-state concentrations are reached after roughly 5 to 7 days of consistent dosing. Measuring a serum concentration before steady state is reached will underestimate the eventual steady-state value and can lead to inappropriate dose escalation. The same principle applies after any dose change: allow 5 to 7 days before rechecking. ## Assay Considerations and Interpretation Therapeutic drug monitoring of digoxin relies on immunoassay techniques, including radioimmunoassay and automated immunoassay platforms. The choice of assay matters because metabolite cross-reactivity differs markedly between methods. Research on anti-digoxin antisera has demonstrated that assay systems can be designed to measure either unmetabolized digoxin specifically or total immunoreactivity weighted toward cardioactive metabolites. For clinical TDM, the latter approach is preferable because it approximates the true pharmacological activity of the drug and its metabolites. When interpreting a reported digoxin concentration, the clinician should consider three questions. First, was the sample drawn at steady state? Second, was the sample timed appropriately relative to the last dose? Third, does the assay used by the laboratory measure the clinically relevant analyte? A concentration drawn too early after dosing reflects the absorptive and distributive phase instead of the steady-state trough, and a concentration measured by an assay with high cross-reactivity to inactive metabolites may not reflect therapeutic effect. ## Relationship Between Serum Concentration and Clinical Effect The therapeutic range for digoxin in dogs is generally cited as 0.7 to 3.0 ng/mL, a range supported by early pharmacokinetic studies in which dogs receiving digoxin at 0.022 mg/kg per day achieved serum concentrations within this window. Concentrations below the lower bound are associated with suboptimal inotropic and rate-control effects, while concentrations above the upper bound carry an increasing risk of toxicity. However, the therapeutic range is a population-based guide, not an absolute threshold for individual patients. Some dogs show adequate clinical response at concentrations below 0.7 ng/mL, and others develop toxicity at concentrations within the accepted range, particularly in the presence of hypokalemia, hypomagnesemia, or advanced myocardial disease. The clinical response must therefore be interpreted alongside the serum concentration. A dog with controlled heart failure and a serum digoxin concentration of 0.6 ng/mL does not automatically require a dose increase if clinical signs are well managed. Conversely, a dog with anorexia, vomiting, or arrhythmias and a concentration of 2.5 ng/mL should be evaluated for toxicity even though the value falls within the reference range. ## Renal Function and Dose Individualization Because digoxin clearance is predominantly renal, assessment of renal function is mandatory before initiating therapy and before any dose adjustment. Serum creatinine concentration and estimated glomerular filtration rate provide the basis for selecting a starting dose and for determining how aggressively to monitor. In dogs with renal insufficiency, the dosing interval should be extended instead of the individual dose reduced, because the prolonged elimination half-life means that a reduced dose at the same interval will still accumulate toward toxic steady-state concentrations. This principle aligns with general geriatric pharmacology guidance that recommends selecting drugs with nonrenal elimination when possible and using TDM to tailor regimens when such selection is not feasible. In patients with acute kidney injury or those undergoing renal replacement therapy, digoxin pharmacokinetics become even less predictable. Drug clearance during continuous venovenous hemofiltration depends on membrane characteriztics, blood flow, and ultrafiltration rate, and empirical dose adjustment based on estimated creatinine clearance is unreliable. In such patients, more frequent monitoring is warranted, and the clinician should be prepared to withhold digoxin until a measured concentration guides the next dose. ## Sampling Protocol and Timing The timing of blood collection determines whether a measured digoxin concentration can be interpreted at all. A sample drawn at the wrong time relative to dosing is clinically meaningless and may prompt inappropriate dose changes. Digoxin follows a two-compartment distribution model. After oral administration, absorption and distribution continue for 6 to 8 hours. Serum concentrations during this period reflect ongoing tissue uptake, not steady-state conditions. Samples collected earlier overestimate the concentration that the myocardium and other tissues are actually exposed to. The standard sampling window is 8 to 12 hours after the last oral dose. This trough sample approximates the post-distributive concentration that correlates best with both therapeutic effect and toxicity risk. Samples drawn before 6 hours post-dose should be rejected and redrawn at the correct interval. Steady-state conditions must be established before interpreting any single concentration. Digoxin has a half-life of approximately 24 to 36 hours in dogs with normal renal function. Steady state is reached after 5 to 7 days of consistent dosing. Samples collected before steady state will read lower than the eventual plateau and may lead to inappropriate dose escalation. For dogs started on digoxin, the first monitoring sample should be collected 7 to 10 days after therapy initiation. This allows steady state to develop and captures any accumulation in patients with subclinical renal impairment. A second confirmatory sample is reasonable 7 days after any dose adjustment. ## Interpretation of Serum Concentrations The accepted therapeutic reference range for dogs is 0.7 to 2.4 ng/mL when measured by immunoassay. Concentrations below 0.7 ng/mL are generally associated with inadequate inotropic and chronotropic effect, although some dogs with mild disease respond at lower levels. Concentrations above 2.4 ng/mL carry a substantially increased risk of toxicity, and the margin between therapeutic effect and toxicity narrows progressively above 2.0 ng/mL. Interpretation must always incorporate the clinical context. A concentration of 2.2 ng/mL in a dog with normal renal function, no electrolyte abnormalities, and no clinical signs of toxicity may be acceptable if the drug is providing meaningful clinical benefit. The same concentration in a dog with hypokalemia, azotemia, or concurrent use of drugs that increase digoxin exposure warrants dose reduction. | Serum concentration (ng/mL) | Interpretation | Recommended action | |---|---|---| | Below 0.7 | Subtherapeutic | Confirm owner compliance and sampling timing. Increase dose by 10 to 20 percent and recheck in 7 days. | | 0.7 to 1.5 | Therapeutic, low end | Continue current dose. Recheck in 3 to 6 months or if clinical status changes. | | 1.5 to 2.4 | Therapeutic, upper range | Continue if clinical response is adequate and no signs of toxicity. Monitor renal values and electrolytes. | | 2.4 to 3.0 | Supratherapeutic | Reduce dose by 20 to 25 percent. Recheck in 7 days. Evaluate for concurrent drug interactions. | | Above 3.0 | Toxic range | Withhold the next dose, then restart at a 25 to 50 percent lower dose. Assess renal function and electrolytes. If clinical toxicity is present, hospitalize and manage supportively. | The table above assumes a trough sample at steady state. Any deviation from this protocol invalidates the interpretation and requires a redraw. ## Factors That Alter Measured Concentrations Renal function is the dominant determinant of digoxin clearance. The drug is eliminated primarily by glomerular filtration and tubular secretion. A decline in creatinine clearance prolongs the elimination half-life and raises steady-state concentrations for any given dose. Dogs with chronic kidney disease, particularly those with International Renal Interest Society stage 3 or 4 disease, require dose reductions of 30 to 50 percent from the standard starting dose and more frequent monitoring. Geriatric patients frequently have reduced renal reserve despite normal serum creatinine concentrations, and therapeutic drug monitoring is specifically recommended in this population to tailor the dosage regimen to the individual patient [Dowling, Geriatric pharmacology](https://pubmed.ncbi.nlm.nih.gov/15833558/). Electrolyte disturbances alter the pharmacodynamic response to digoxin independent of serum concentration. Hypokalemia potentiates digoxin toxicity at concentrations that would otherwise be tolerated. Hypomagnesemia has a similar effect. Hypercalcemia also increases sensitivity to digoxin. A serum concentration of 2.0 ng/mL may produce toxicity in a hypokalemic dog but be well tolerated in a normokalemic dog. Serum potassium and magnesium should be measured whenever a concentration falls in the upper therapeutic range or above. Drug interactions change digoxin concentrations through multiple mechanisms. Amiodarone, verapamil, diltiazem, and quinidine reduce digoxin clearance and increase serum concentrations by 30 to 100 percent. Spironolactone can interfere with some digoxin assays and may also reduce tubular secretion. When any of these drugs is added to a stable digoxin regimen, a monitoring sample should be collected 7 days after the change. Assay methodology affects the measured value. Immunoassays vary in their cross-reactivity with digoxin metabolites, and some assays detect inactive metabolites that inflate the reported concentration. Assays that use monoclonal antibodies with cross-reactivity patterns that parallel the biological activity of digoxin metabolites provide a more accurate estimate of pharmacologically active drug [Miller et al., Digoxin immunoassay with cross-reactivity of digoxin metabolites](https://pubmed.ncbi.nlm.nih.gov/7923769/). Laboratories should be asked which assay platform they use, and serial monitoring should be performed on the same platform to avoid inter-assay variation. ## Monitoring Schedule for Stable Patients Once a dog is stabilized on digoxin with a therapeutic trough concentration, monitoring continues at defined intervals. The schedule below reflects current practice recommendations and should be adjusted for individual patient risk. | Time point | Tests | Rationale | |---|---|---| | Baseline before starting digoxin | Serum creatinine, BUN, potassium, magnesium, total T4 if hyperthyroidism is suspected | Identifies patients requiring dose reduction and establishes baseline renal function | | 7 to 10 days after initiation | Digoxin trough, serum creatinine, potassium | Confirms steady-state concentration and detects early accumulation | | 7 days after any dose adjustment | Digoxin trough | Verifies that the new dose produces a therapeutic concentration | | Every 3 to 6 months in stable patients | Digoxin trough, serum creatinine, potassium, body weight | Detects gradual changes in renal function or body mass that alter drug disposition | | Within 7 days of adding an interacting drug | Digoxin trough | Captures the effect of the drug interaction before toxicity develops | | Immediately if clinical signs suggest toxicity | Digoxin trough, serum creatinine, potassium, magnesium, ECG | Confirms toxicity and guides emergency management | Body weight changes matter because digoxin dosing is weight-based and the volume of distribution changes with lean body mass. A dog that loses significant muscle mass may have a relatively higher serum concentration for the same dose. Weight should be recorded at every monitoring visit. ## Recognition and Management of Digoxin Toxicity Clinical signs of digoxin toxicity include anorexia, vomiting, diarrhea, lethargy, and weakness. Cardiac signs include bradyarrhythmias, atrioventricular block, ventricular premature complexes, and supraventricular arrhythmias. Gastrointestinal signs often precede cardiac signs and may be mistaken for the underlying heart disease worsening. Any dog receiving digoxin that develops anorexia or vomiting should have a serum digoxin concentration measured before the next dose is administered. The drug should be withheld until the result is available. This approach avoids the common error of continuing digoxin while the clinical signs are attributed to heart failure or another comorbidity. Management of confirmed toxicity depends on severity. For mild toxicity with concentrations between 2.4 and 3.0 ng/mL and no cardiac arrhythmias, withholding one or two doses and restarting at a lower dose may suffice. For moderate toxicity with gastrointestinal signs and concentrations above 3.0 ng/mL, digoxin should be discontinued for 24 to 48 hours, then restarted at a 25 to 50 percent lower dose once the concentration falls below 2.0 ng/mL. Severe toxicity with hemodynamically significant arrhythmias requires hospitalization. Intravenous fluid therapy, correction of electrolyte abnormalities, and continuous electrocardiographic monitoring are indicated. Antiarrhythmic therapy should be selected based on the specific arrhythmia. Digoxin-specific antibody fragments are the definitive antidote but are expensive and may not be readily available in general practice. The decision to use them should balance cost against the severity of the arrhythmia and the likelihood of spontaneous recovery. Renal function should be reassessed in any dog that develops digoxin toxicity. A decline in creatinine clearance may have occurred since the last monitoring visit, and the dose must be adjusted to the current renal status. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides additional guidance on the clinical management of cardiac glycoside toxicity in dogs. ## Documentation and Communication Monitoring results should be recorded in the medical record with the following elements: the date and time of the last digoxin dose, the date and time of blood collection, the assay platform used, the serum concentration, concurrent renal values and electrolytes, body weight, and the clinical assessment. This documentation allows longitudinal comparison and supports dose decisions made at subsequent visits. The owner should be informed of the monitoring schedule and the reason for each blood draw. They should also be instructed to report anorexia, vomiting, or lethargy promptly instead of waiting for the next scheduled visit. Owner observations are often the first indicator of a rising digoxin concentration and should be taken seriously even when the most recent measured concentration was therapeutic. ## Recognized Complications and Early Detection The principal failure modes in digoxin therapy are toxicity, subtherapeutic effect, and misinterpretation of measured concentrations. Toxicity remains the most consequential complication because the therapeutic index is narrow and clinical signs overlap with the underlying cardiac disease. Gastrointestinal signs, anorexia, and lethargy are the earliest indicators of digoxin intoxication in dogs. These signs precede cardiac arrhythmias in most cases, which provides a clinical window for intervention. Vomiting and diarrhea may be mistaken for progression of congestive heart failure or an unrelated gastrointestinal disorder, so any dog receiving digoxin that develops these signs warrants a serum concentration measurement before empirical treatment is changed. Cardiac toxicity manifests as bradyarrhythmias, atrioventricular block, ventricular ectopy, or supraventricular tachyarrhythmias. Electrocardiography should be performed whenever toxicity is suspected, and continuous telemetry is indicated for hospitalized dogs with confirmed or suspected intoxication. Neurologic signs such as weakness, disorientation, or seizures occur in severe cases and carry a guarded prognosis. Renal function decline is a silent predisposing factor. Digoxin elimination depends heavily on renal excretion, and a dog stabilized on a given dose can become toxic when azotaemia develops from progression of heart failure, intercurrent disease, or nephrotoxic drug exposure. Serial measurement of serum creatinine and symmetric dimethylarginine should accompany each digoxin concentration check in older dogs, since age-related renal senescence reduces clearance unpredictably [Dowling, Geriatric pharmacology](https://pubmed.ncbi.nlm.nih.gov/15833558/). Hypokalemia potentiates digoxin toxicity at any given serum concentration. Loop diuretics used concurrently for heart failure management are the most common cause. Serum potassium should be measured at each monitoring visit, and supplementation or diuretic dose adjustment should precede any decision to lower the digoxin dose. ## Common Errors and Corrective Actions The most frequent error is sampling too early. A blood sample drawn before steady state is reached produces a misleadingly low or high value depending on the timing relative to the last dose. Trough sampling after at least five elimination half-lives, approximately 5 to 7 days after initiation or dose change, is the standard that avoids this error. A second error is interpreting a single concentration in isolation. The measured value must be assessed against the clinical response, the electrocardiogram, renal function, and the assay's cross-reactivity profile. Immunoassays vary in how they detect digoxin metabolites, and some overestimate the pharmacologically active fraction because they cross-react with inactive or weakly active breakdown products [Miller et al., Digoxin immunoassay with cross-reactivity of digoxin metabolites](https://pubmed.ncbi.nlm.nih.gov/7923769/). A concentration near the upper therapeutic limit in a dog with no signs of toxicity does not automatically mandate dose reduction, particularly if the assay used is known to over-read metabolites. A third error is failing to recheck concentrations after a change in concurrent medication. The addition of agents that alter renal perfusion, displace protein binding, or affect P-glycoprotein transport can shift the steady-state concentration without any change in digoxin dose. A monitoring plan that assumes stability in the face of polypharmacy is unsafe. A fourth error is treating the number instead of the patient. A subtherapeutic concentration in a dog with controlled clinical signs does not require dose escalation. Conversely, a therapeutic concentration in a dog with anorexia or arrhythmias does not exclude toxicity, since individual sensitivity varies with electrolyte status, myocardial disease severity, and concurrent drug exposure. | Observation | Likely cause | Discriminating check | |---|---|---| | Low trough concentration after 7 days | Non-adherence, malabsorption, sampling too early | Confirm dosing history, verify steady state, repeat sample | | High trough concentration, no clinical signs | Assay cross-reactivity with metabolites, sampling near peak | Review assay type, confirm trough timing, check renal function | | Toxicity signs with therapeutic concentration | Hypokalemia, advanced myocardial disease, drug interaction | Measure potassium, perform ECG, review concurrent medications | | Rising concentration on stable dose | Declining renal function | Measure creatinine and symmetric dimethylarginine | | Anorexia without vomiting | Early toxicity or heart failure progression | Measure digoxin concentration, assess cardiac status | ## Limitations of the Evidence The evidence base for digoxin monitoring in dogs relies heavily on extrapolation from human medicine and on older pharmacokinetic studies. Controlled prospective trials correlating serum concentrations with clinical outcomes in canine heart failure are scarce. The commonly cited therapeutic range of 0.7 to 3.0 ng/mL derives from early work, including studies of liposomal digoxin formulations, and may not reflect optimal targets for modern heart failure protocols [Fountain et al., Serum concentrations of digoxin entrapped in liposomes](https://pubmed.ncbi.nlm.nih.gov/7249412/). Expert opinion differs on the upper boundary of the therapeutic range. Some clinicians accept concentrations up to 2.5 ng/mL in dogs with severe myocardial failure, while others cap at 2.0 ng/mL to reduce toxicity risk. The lower boundary is similarly debated, with some authors arguing that clinical response should override a low measured value. Assay standardization compounds the uncertainty, since metabolite cross-reactivity varies by platform and can shift reported values by 20% or more [Ikeda and Fujii, Properties of novel anti-digoxin antisera in radioimmunoassay](https://pubmed.ncbi.nlm.nih.gov/15684495/). The interaction between digoxin and modern heart failure drugs, including pimobendan and angiotensin-converting enzyme inhibitors, has not been rigorously studied for its effect on digoxin pharmacokinetics. Clinicians should therefore monitor more frequently when these combinations are used. ## Referral and Escalation Referral to a veterinary cardiologist is warranted when toxicity produces hemodynamically significant arrhythmias, when heart failure remains refractory despite therapeutic digoxin concentrations, or when the indication for digoxin is uncertain. A cardiologist can provide echocardiographic assessment, advanced rhythm management, and alternative inotropic or antiarrhythmic strategies. Laboratory involvement is appropriate when assay results conflict with clinical findings, when a different assay platform is being considered, or when metabolite interference is suspected. The laboratory should be consulted about the specific assay's cross-reactivity characteriztics before interpreting borderline values. Regulatory reporting is not typically required for digoxin adverse events in companion animals. However, suspected product defects, such as tablet potency variation or formulation failure, should be reported to the manufacturer and to the relevant regulatory authority. The FDA Center for Veterinary Medicine maintains adverse event reporting pathways for approved animal drugs [FDA CVM animal drug information](https://www.fda.gov/animal-veterinary). Clinicians should document the event, the product lot number, and the clinical outcome to support any investigation. ## Frequently Asked Questions ### How should I proceed when therapeutic drug monitoring is unavailable in my practice? When serum digoxin measurement is not accessible, rely on clinical monitoring and conservative dosing. Assess renal function before initiating therapy, since reduced clearance increases toxicity risk. Monitor heart rate, appetite, and gastrointestinal signs at each recheck. Electrocardiography provides objective evidence of drug effect, including PR interval prolongation and atrioventricular block. Geriatric patients warrant particular caution, as age-related changes in drug disposition are common and therapeutic drug monitoring is specifically recommended in this population when available [Dowling on geriatric pharmacology](https://pubmed.ncbi.nlm.nih.gov/15833558/). If the patient deteriorates clinically, reduce the dose or discontinue the drug instead of persisting without concentration data. ### What does a low measured digoxin concentration mean when the clinical response appears adequate? A subtherapeutic serum concentration with satisfactory clinical control does not automatically mandate a dose increase. The therapeutic range represents a population-derived probability of benefit, not an absolute threshold for every patient. Some dogs respond well at concentrations below 0.7 ng/mL, particularly when digoxin is used as an adjunct to other cardiac medications. Confirm the sample was collected at steady state, at least 8 hours after the last dose, and that the assay used is appropriate. Assays vary in cross-reactivity with digoxin metabolites, and some overestimate or underestimate pharmacologically active drug [Miller et al. on digoxin immunoassay cross-reactivity](https://pubmed.ncbi.nlm.nih.gov/7923769/). If sampling and assay are validated, continue the current dose and monitor clinically. ### How do I manage a dog with renal insufficiency that requires digoxin? Renal impairment reduces digoxin clearance and prolongs elimination half-life, so steady-state concentrations rise unpredictably. Measure serum creatinine and estimate glomerular filtration rate before starting therapy. Initiate at a lower dose and extend the dosing interval instead of reducing the dose alone, since peak concentrations depend on distribution volume while trough accumulation reflects clearance. Recheck serum digoxin concentration 5 to 7 days after any dose adjustment. If therapeutic drug monitoring is unavailable, select alternative inotropic support or use digoxin at the lowest effective dose with frequent clinical and electrocardiographic assessment. Geriatric patients with renal disease are at particular risk, and drug selection should favour agents with non-renal elimination where possible [Dowling on geriatric pharmacology](https://pubmed.ncbi.nlm.nih.gov/15833558/). ### What should I tell an owner when their dog develops suspected digoxin toxicity? Explain that digoxin has a narrow margin between therapeutic and toxic concentrations and that signs such as vomiting, lethargy, or collapse require immediate veterinary attention. Instruct the owner to stop the medication and bring the dog in for examination instead of waiting for the next scheduled dose. Describe what will happen next: a physical examination, electrocardiogram, serum digoxin measurement, and renal biochemistry. Reassure the owner that toxicity is manageable when detected early and that the drug can often be resumed at a lower dose once concentrations normalize. Advise them to keep the medication container and record the time of the last dose, as this information directly guides interpretation of the serum concentration. ### Can digoxin monitoring principles be applied to other species in my practice? The fundamental principles of therapeutic drug monitoring, including steady-state sampling, timing relative to the last dose, and interpretation against a species-specific reference range, apply broadly. However, the canine therapeutic range of 0.7 to 3.0 ng/mL should not be extrapolated to cats or exotic species without supporting evidence. Feline patients have different digoxin pharmacokinetics and a narrower therapeutic window. Assay performance also varies between species because metabolite profiles differ, and an assay validated for canine samples may not accurately measure drug in another species [Miller et al. on digoxin immunoassay cross-reactivity](https://pubmed.ncbi.nlm.nih.gov/7923769/). Consult species-specific pharmacology references before applying canine monitoring protocols elsewhere. ### How should I document digoxin monitoring in the medical record? Record the indication for therapy, the dose prescribed, and the rationale for that dose, including body weight and renal status. For each serum concentration measurement, document the sampling date and time, the time of the last administered dose, the assay used, and the laboratory reference range. Note the clinical status at the time of sampling, including heart rate, rhythm, appetite, and any gastrointestinal signs. Record the interpretation and the specific action taken, whether continuing the current dose, adjusting the dose, or discontinuing therapy. Include owner communication about toxicity signs and the plan for follow-up monitoring. This documentation supports continuity of care and provides a defensible record if questions arise about clinical decisions. ## Related Clinical & Scientific Guides * [Veterinary Formulary Essentials: Navigating Drug References](/knowledge/veterinary-medicine/clinical-pharmacology/veterinary-formulary-essentials-navigating-drug-references) * [Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-antiepileptic-veterinary) * [Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review](/knowledge/veterinary-medicine/clinical-pharmacology/drug-interactions-corticosteroids-veterinary-comprehensive) ## References and Further Reading - [Geriatric pharmacology.](https://pubmed.ncbi.nlm.nih.gov/15833558/). 2005. - [Serum concentrations of digoxin entrapped in liposomes after intravenous administration in dogs.](https://pubmed.ncbi.nlm.nih.gov/7249412/). 1981. - [Digoxin immunoassay with cross-reactivity of digoxin metabolites proportional to their biological activity.](https://pubmed.ncbi.nlm.nih.gov/7923769/). 1994. - [Xysmalobium undulatum (uzara) - review of an antidiarrhoeal traditional medicine.](https://pubmed.ncbi.nlm.nih.gov/25193007/). 2014. - [Properties of novel anti-digoxin antisera in radioimmunoassay using homologous and site heterologous tritium-labeled antigens involving a [3H]-leucine moiety.](https://pubmed.ncbi.nlm.nih.gov/15684495/). 2005. - [Drug clearance during Continuous Veno-Venous Hemofiltration (CVVH). A mathematical model based on ex-vivo experiments](https://doi.org/10.1111/j.1365-2125.2007.02886_7.x). 2007. - [FDA Center for Veterinary Medicine: Animal Drug Information](https://www.fda.gov/animal-veterinary). FDA CVM. - [AVMA Antimicrobial Use and Stewardship](https://www.avma.org/resources-tools/one-health/antimicrobial-use-and-antimicrobial-resistance). American Veterinary Medical Association. - [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual. ## Related Articles - [Therapeutic Drug Monitoring of Aminoglycosides in Veterinary Patients: Indications and Protocols](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-aminoglycosides) - [Therapeutic Drug Monitoring of Cyclosporine in Veterinary Dermatology: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-cyclosporine) - [Therapeutic Drug Monitoring in Veterinary Practice: Indications and Interpretation](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-veterinary-practice-indications-interpretation) - [Therapeutic Drug Monitoring in Epileptic Dogs: Antiepileptic Drug Levels](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-drug-monitoring-epileptic-dogs-antiepileptic-drug-levels) - [Therapeutic Decision Framework for Canine Osteoarthritis: NSAIDs, Adjuvants, and Monitoring](/knowledge/veterinary-medicine/clinical-pharmacology/therapeutic-decision-framework-canine-osteoarthritis) > This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.